106 related articles for article (PubMed ID: 24861196)
21. Resveratrol interferes with N-nitrosodiethylamine-induced hepatocellular carcinoma at early and advanced stages in male Wistar rats.
Rajasekaran D; Elavarasan J; Sivalingam M; Ganapathy E; Kumar A; Kalpana K; Sakthisekaran D
Mol Med Rep; 2011; 4(6):1211-7. PubMed ID: 21850372
[TBL] [Abstract][Full Text] [Related]
22. Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib.
Thakur S; Ruan Y; Jayanthan A; Boklan J; Narendran A
Curr Cancer Drug Targets; 2021; 21(9):804-811. PubMed ID: 33949932
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of altered liver cell foci and persistent nodule growth by vanadium during diethylnitrosamine-induced hepatocarcinogenesis in rats.
Bishayee A; Chatterjee M
Anticancer Res; 1995; 15(2):455-61. PubMed ID: 7763021
[TBL] [Abstract][Full Text] [Related]
24. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
Park JE; Chun SE; Reichel D; Min JS; Lee SC; Han S; Ryoo G; Oh Y; Park SH; Ryu HM; Kim KB; Lee HY; Bae SK; Bae Y; Lee W
PLoS One; 2017; 12(3):e0173247. PubMed ID: 28273121
[TBL] [Abstract][Full Text] [Related]
25. Potential chemoprevention of diethylnitrosamine-induced hepatocarcinogenesis in rats: myrrh (Commiphora molmol) vs. turmeric (Curcuma longa).
El-Shahat M; El-Abd S; Alkafafy M; El-Khatib G
Acta Histochem; 2012 Sep; 114(5):421-8. PubMed ID: 21871653
[TBL] [Abstract][Full Text] [Related]
26. Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation.
Agbana P; Park JE; Rychahou P; Kim KB; Bae Y
J Pharm Sci; 2024 Mar; 113(3):711-717. PubMed ID: 37673172
[TBL] [Abstract][Full Text] [Related]
27. Chemopreventive evaluation of Tephrosia purpurea against N-nitrosodiethylamine-induced hepatocarcinogenesis in Wistar rats.
Hussain T; Siddiqui HH; Fareed S; Vijayakumar M; Rao CV
J Pharm Pharmacol; 2012 Aug; 64(8):1195-205. PubMed ID: 22775223
[TBL] [Abstract][Full Text] [Related]
28. Anti-tumor effects of cimetidine on hepatocellular carcinomas in diethylnitrosamine-treated rats.
Furuta K; Sato S; Miyake T; Okamoto E; Ishine J; Ishihara S; Amano Y; Adachi K; Kinoshita Y
Oncol Rep; 2008 Feb; 19(2):361-8. PubMed ID: 18202782
[TBL] [Abstract][Full Text] [Related]
29. Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine.
Fiume L; Bolondi L; Busi C; Chieco P; Kratz F; Lanza M; Mattioli A; Di Stefano G
J Hepatol; 2005 Oct; 43(4):645-52. PubMed ID: 16023760
[TBL] [Abstract][Full Text] [Related]
30. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
31. Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
Agbana P; Lee MJ; Rychahou P; Kim KB; Bae Y
Pharm Res; 2020 Oct; 37(11):213. PubMed ID: 33025286
[TBL] [Abstract][Full Text] [Related]
32. Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
Lee MJ; Bhattarai D; Yoo J; Miller Z; Park JE; Lee S; Lee W; Driscoll JJ; Kim KB
J Med Chem; 2019 May; 62(9):4444-4455. PubMed ID: 30964987
[TBL] [Abstract][Full Text] [Related]
33. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
34. Effect of antisense oligomer in controlling c-raf.1 overexpression during diethylnitrosamine-induced hepatocarcinogenesis in rat.
Das T; Patra F; Mukherjee B
Cancer Chemother Pharmacol; 2010 Jan; 65(2):309-18. PubMed ID: 19499222
[TBL] [Abstract][Full Text] [Related]
35. 1alpha, 25-Dihydroxyvitamin D3 suppresses the effect of streptozotocin-induced diabetes during chemical rat liver carcinogenesis.
Saha BK; Sarkar A; Basak R; Chatterjee M
Cell Biol Int; 2001; 25(3):227-37. PubMed ID: 11352495
[TBL] [Abstract][Full Text] [Related]
36. Polyol profile as an early diagnostic and prognostic marker in natural product chemoprevention of hepatocellular carcinoma in diabetic rats.
Abdel-Hamid NM; Nazmy MH; Abdel-Bakey AI
Diabetes Res Clin Pract; 2011 May; 92(2):228-37. PubMed ID: 21388699
[TBL] [Abstract][Full Text] [Related]
37. A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo.
Zhang C; Wang X; Cheng R; Zhong Z
Biomacromolecules; 2020 Jun; 21(6):2049-2059. PubMed ID: 32338875
[TBL] [Abstract][Full Text] [Related]
38. Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro.
Li Y; Li J; Zhuang W; Wang Q; Ge X; Zhang X; Chen P; Fu J; Li B
Leuk Res; 2014 Aug; 38(8):970-6. PubMed ID: 24939218
[TBL] [Abstract][Full Text] [Related]
39. Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.
Park JE; Park J; Jun Y; Oh Y; Ryoo G; Jeong YS; Gadalla HH; Min JS; Jo JH; Song MG; Kang KW; Bae SK; Yeo Y; Lee W
J Control Release; 2019 May; 302():148-159. PubMed ID: 30954620
[TBL] [Abstract][Full Text] [Related]
40. The prophylactic and therapeutic effects of Momordica charantia methanol extract through controlling different hallmarks of the hepatocarcinogenesis.
Ali MM; H Borai I; Ghanem HM; H Abdel-Halim A; Mousa FM
Biomed Pharmacother; 2018 Feb; 98():491-498. PubMed ID: 29287196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
